Lupin receives USFDA approval for Potassium Chloride for Oral Solution

Image
Capital Market
Last Updated : Nov 26 2018 | 6:04 PM IST
Lupin has received approval for its Potassium Chloride for Oral Solution USP, 20 mEq from the United States Food and Drug Administration (FDA) to market a generic version of Pharma Research Software Solution LLC's Potassium Chloride for Oral Solution, 20 mEq.

Lupin's Potassium Ch oride for Oral Solution USP, 20 mEq is the generic version of Pharma Research Software Solution, LLC's Potassium Chloride for Oral Solution, 20 mEq. It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.

Potassium Chloride for Oral Solution USP, 20 mEq had annual sales of approximately USD 105 million in the US (IQVIA MAT September 2018).

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 26 2018 | 5:41 PM IST

Next Story